OOIR: Observatory of International Research

Papers

(The H4-Index of Best Practice & Research Clinical Endocrinology & Metabolism is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
The novel concept of “Onco-Immuno-Endocrinology” led to the discovery of new clinical entity “paraneoplastic autoimmune hypophysitis”	114
Editorial Board	112
Editorial Board	78
Editorial Board	74
Genetics of pubertal timing	64
Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine	57
Growth hormone replacement in adults with cured acromegaly: Efficacy and safety	55
Recent progress in molecular classification of phaeochromocytoma and paraganglioma	53
Gonadectomy in individuals with a difference of sex development – For whom, when, why, and why not?	51
Menopausal hormone therapy for the management of osteoporosis	48
Regulation of bone mass: A splendid Orchestra	45
Polygenic risk scores for dyslipidemia and atherosclerotic cardiovascular disease: Progress toward clinical implementation	44
Coronavirus disease 2019 and vitamin D	44
Rare forms of genetic steroidogenic defects affecting the gonads and adrenals	41
Editorial Board	41
The role of androgens in transgender medicine	40
Sexual health and contraception in the menopause journey	40
Prenatal exposure to phthalate esters and its impact on child development	39
Editorial Board	39
Immune checkpoint inhibitor-related thyroid dysfunction	39
Optimal surgical approach for digestive neuroendocrine neoplasia primaries: Oncological benefits versus short and long-term complications	38
Remnant lipoprotein particles and cardiovascular disease risk	34
Cardiometabolic outcomes of early onset hypogonadism in males	34
Haematological actions of androgens	32
Acquired disorders of phosphaturia: Beyond tumor-induced osteomalacia	31

Molecular basis of symptomatic sporadic primary hyperparathyroidism: New frontiers in pathogenesis	31
Editorial Board	28
Safety of long-term use of daily and long-acting growth hormone in growth hormone-deficient adults on cancer risk	27
Epidemiology and risk factors for hypopituitarism due to traumatic brain injury	27